Application of brentuximab vedotin in Hodgkin lymphoma / 白血病·淋巴瘤

ABSTRACT

Reed-Sternberg cells of Hodgkin lymphoma (HL) typically express CD30, while CD30 is rarely expressed in normal cells and can be rapidly internalized, making it an ideal target for monoclonal antibodies and antibody-drug conjugates. Brentuximab vedotin (BV) is a novel CD30-directed antibody-conjugated drug, and it is a landmark in HL treatment history. This article will describe the efficacy, tolerability and safety of BV as consolidation, salvage and combination therapy in HL.